Shandong Granberg Biopharmaceutical

Shandong Granberg Biopharmaceutical is a Chinese biotechnology company focused on the development of innovative metabolic and endocrine therapies. The company specializes in the research and development of peptide-based drugs and small molecules, with a particular emphasis on multi-receptor agonists targeting GLP-1, GIP, and Glucagon receptors. Based in Shandong Province, the firm aims to address significant unmet medical needs in chronic conditions such as obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). Shandong Granberg leverages advanced peptide synthesis and modification technologies to create long-acting therapeutic candidates with improved efficacy and safety profiles.